Amerikanische Gesellschaft für Hirudotherapie

Invertebrate compounds acting on the hemostatic mechanism

Review published in Blood Coagul Fibrinolysis (1999)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewSpeichel-PharmakologieArzneimittelentwicklungArocha-Pinango CL et al. · Blood Coagul Fibrinolysis, 1999

Abstract

Physiological secretions from some invertebrates have toxic effects on mammalian blood coagulation and fibrinolytic systems. Some of these effects occur because the substances contained in the secretions resemble the components of the hemostatic system. Some of the substances have been characterized, and have been found to have similar molecular weights or sequences, which may indicate a common ancestry. The components can be divided into five groups: antithrombic agents (group I); inhibitors and activators of the prothrombinase complex (group II); substances that affect platelet function (group III); substances that affect the fibrinolytic mechanism (group IV); and a group of miscellaneous agents whose activities are difficult to group together (group V). In group I special mention of the antithrombin agents in Hirudo medicinalis should be made. In group II, the agents affecting the prothrombinase complex are antistasin from Haementeria officinalis, ghilanten from Haementeria Ghiliani and the tick anticoagulant protein from Ornithodoros moubata, a factor V activator/inhibitor from Lonomia achelous and factor II and factor X activators from L. achelous and Lonomia obliqua. Examples of factors which affect platelet function (group III) are glossina from the black fly Glossina morsitans, calin from H. medicinalis, decorsin (a desintegrin) from Macrobdella decorsa, and FAGA from Stichopus japonicus selenka. The first three of these are inhibitors of platelet aggregation, and the last is an inducer. The plasminogen activators (group IV) from the L. achelous caterpillar and Eutriatoma maculata trigger the fibrinolytic system, whereas hementin from H. officinalis and hementerin from Haementeria depressa are directly fibrinolytic. The last group of substances (group V) include those with factor-XIIa-like activity from D. farinae, kallikrein-like activity and a factor XIII degrading enzyme from L. achelous, destabilase from H. medicinalis and prolixin S (nitroforin 2, or anti-factor-IXa) from Rhodnius prolixus. Some of these components have been well characterized, cloned and prepared in recombinant form, and seem to be very promising from the therapeutic point of view.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnimalsBiological FactorsBlood PlateletsFactor VFactor XFactor XaFibrinHematologic AgentsHemostasisHumansInvertebratesThrombin

Zusammenfassung

Comprehensive review of invertebrate secretions with toxic effects on mammalian blood coagulation and fibrinolytic systems, including hirudin, antistasin, ghilanten, calin, decorsin, hementin, and destabilase.

Warum dies für die Hirudotherapie relevant ist

This review article surveys a wide array of invertebrate-derived physiological secretions that affect the mammalian hemostatic and fibrinolytic systems. It categorizes these biological factors into five groups based on their mechanisms, prominently featuring substances from leeches, including antithrombin agents and calin from Hirudo medicinalis, decorsin from Macrobdella decorsa, and destabilase from H. medicinalis. The abstract notes that some of these components have been well characterized, cloned, and prepared in recombinant form, showing therapeutic promise. This paper is relevant to the American Society of Hirudotherapy because it details the biochemical diversity and pharmacological potential of specific compounds derived from medicinal leeches. However, its scope is broad and covers many non-leech invertebrates.

Zitation

Invertebrate compounds acting on the hemostatic mechanism.

Arocha-Pinango CL et al. · Blood Coagul Fibrinolysis, 1999

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.